Behavioral Therapy Development for Methamphetamine Abusers

The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings Clinical Trial

Official title:

Behavioral Therapy Development for Methamphetamine Abuse

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT00249678
• Other study ID #: NIDA-18075-1
• Secondary ID: R21DA018075R21-1
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 2004
• Est. completion date: May 2007

Study information

• Verified date: February 2020
• Source: University of California, Los Angeles
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is...to assess whether placing a substance abuse intervention for HIV+ methamphetamine users within an HIV medical care setting improves rates of follow-up on referral to treatment by primary care physicians; reduces drug use and sexual risk behaviors more than treatment-as-usual; and increases rates of adherence to HIV medication regimens.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: May 2007
• Est. primary completion date: May 2007
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. HIV-seropositive, GBM receiving medical treatment for HIV for at least 30 days prior to signing informed consent at the UCLA CARE clinic, aged 18-65

2. Willing to give informed consent and comply with study procedures;

3. Willing to provide consent to contact treating physicians and pharmacies to assess adherence to HIV medications;

4. Diagnosed with current methamphetamine abuse as determined by MINI; and

5. Interested in seeking treatment for their methamphetamine abuse and in participating in this research project.

Exclusion Criteria:

1. Unwilling to give, or withdrawal of, informed consent;

2. Inability to understand nature of study;

3. A psychiatric condition that, in the principal investigator's judgment, warrants additional intervention to ensure participant safety (e.g., meets DSM-IV-TR criteria for current bipolar disorder or a psychotic disorder);

4. Current suicidal ideation or suicide attempt within the past 3 months; and

5. Concurrent dependence on opiates, alcohol, or benzodiazepines as determined by MINI.

6. Total lack of any type of healthcare coverage. These potential participants will be given low-fee treatment referrals.

Related Conditions & MeSH terms

• The Study Was Designed to Develop a Cognitive Behavioral Approach to Treating Methamphetamine Abuse in HIV Primary Care Settings

Intervention

Behavioral:
• Behavior Therapy

Locations

Country	Name	City	State
United States	UCLA CARE Clinic	Los Angeles	California
United States	UCLA Medical Center	Los Angeles	California
United States	UCLA, Integrated Substance Abuse Programs	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of California, Los Angeles	National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Craving
Primary	Medication compliance
Primary	Addiction severity
Primary	Psychiatric interview
Primary	Sex-risk behavior
Secondary	Depression
Secondary	Quality of Life